LAUSR

Biologic disease modifying anti‐rheumatic drugs (DMARDs) are effective for the treatment of rheumatoid arthritis but also expensive. Medicare covers an important part of the cost of biologic DMARDs in the United States; however, studies examining the coverage and cost sharing in Medicare Part D are scarce. The purpose of this study was to examine the formulary coverage and cost sharing of biologic DMARDs in Medicare Part D in the period 2006 to 2015.